跳至主要内容
临床试验/JPRN-UMIN000001460
JPRN-UMIN000001460已完成未知

The efficacy and safety of pirocarpine hydrochloride for juvenile Sjogren's syndrome - Efficacy of pirocarpine for juvenile SS

Department of Pediatrics, Graduate School of Medicine, Chiba Univerity0 个研究点目标入组 10 人开始时间: 2008年10月29日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
6years-old 至 16years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients who fulfills any of following exclusion criteria will be excluded. 1)Secondary Sjogren's syndrome 2)Hypersensitivity to pilocarpine HCl or cevimeline HCl 3)Iritis 4)A condition predisposing to retinal detachment including having retinal breaks or history of retinal breaks 5)Serious gallbladder disease, biliary disease or biliary obstruction 6)Serious nephrolithiasis or ureterolithiasis 7)Bronchial asthma, chronic obstructive lung disease or interstitial pneumonia 8)Gastrointestinal obstruction or bladder neck obstruction 9)Epilepsy 10)Serious cardiac disease including ischemic heart disease, serious arrhythmia, cardiomyopathy or myocarditis 11)Serious vascular disease including aortic aneurysm, aortic dissection 12)Serious cerebrovascular disorder including brain hemorrhage after surgery, stroke, or aortic dissection 13)Serious hepatic disorder including fulminant hepatitis, hepatic cirrhosis, hepatic tumor or total bilirubin level 3.0mg/dL or higher or AST(GOT) or ALT(GPT) of at least 2.5 fold higher than the upper standard limit 14)Serious renal disease including nephritic syndrome, acute nephropathy, acute nephritis, chronic nephritis or serum creatinine level 1.5mg/dL or higher 15)Serious blood disease or hematopoietic system disorder 16)Patients who are considered ineligible for participation in the study by the investigator

研究者

发起方
Department of Pediatrics, Graduate School of Medicine, Chiba Univerity

相似试验